Table 3.

Treatments and clinical outcomes for advanced NSCLC patients by genotype

Genotype
Mutant BRAFWild-type
All (n = 14)V600E (n = 7)Non-V600E (n = 7)(n = 79)
CharacteristicN (%)N (%)N (%)N (%)
Median no. of treatment regimens3332
 Range(1–6)(1–4)(1–6)(1–7)
Best response to chemotherapya
 CR0 (0)0 (0)0 (0)0 (0)
 PR7b (50)2 (29)5 (71)38c (48)
 Stable disease5 (36)3 (43)2 (29)36d (46)
 PD2 (14)2 (29)0 (0)5 (6)
Response rate, %50297148
Median PFS, mo5.24.18.96.7
 (95% CI)(3.9–9.4)(2.2–13.9)(5.2–11.7)(5.0–8.5)

Abbreviation: CR, complete response.

  • aChemotherapy refers to first-line platinum-based combination chemotherapy.

  • bAll seven responses were confirmed by repeat radiographic assessment conducted ≥ 4 weeks after the criteria for response were first met.

  • cSeven of the 38 PRs were not confirmed.

  • dStable disease (n = 29) or non-CR/non-PD (n = 7) for at least 3 weeks (n = 1), 4 weeks (n = 1) or ≥ 6 weeks (n = 34).